Protech Inc(PRTC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -4.6 | Insider Own | - | Shs Outstand | 24.3M | Perf Week | - |
| Market Cap | 0.42B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | - | Perf Month | 4.37% |
| Enterprise Value | - | PEG | - | EPS next Q | - | Inst Own | 0.58% | Short Float | - | Perf Quarter | 1.34% |
| Income | - | P/S | 91.01 | EPS this Y | - | Inst Trans | - | Short Ratio | 0.9 | Perf Half Y | 3.75% |
| Sales | 0.00B | P/B | 1.35 | EPS next 5Y | - | ROA | - | Short Interest | 0.01M | Perf YTD | 4.69% |
| Book/sh | 12.91 | P/C | - | EPS past 3/5Y | - | ROE | - | 52W High | -12.55% ($19.92) | Perf Year | -0.03% |
| Cash/sh | - | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 20.14% ($14.50) | Perf 3Y | -30.65% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -312.58% | Gross Margin | - | Volatility(W/M) | 3.75% 4.31% | Perf 5Y | -66.88% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -3.44% | Oper. Margin | - | ATR (14) | 0.79 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | - | EPS Q/Q | - | Profit Margin | - | RSI (14) | 51.77 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | - | Sales Q/Q | -38.2% | SMA20 | 0.51% ($17.33) | Beta | 1.15 | Target Price | - |
| Payout | - | Debt/Eq | - | Earnings | 2026/4/29 | SMA50 | 3.4% ($16.85) | Rel Volume | 0 | Prev Close | $17.42 |
| Employees | - | LT Debt/Eq | - | EPS/Sales Surpr. | 6.86% -93.19% | SMA200 | 0.45% ($17.34) | Avg Volume(3M) | 0.01M | Price | $17.42 |
| IPO | 2020/11/16 | Option/Short | No/No | Trades | 0 | Volume | - | Change | - |
Company
PRTC is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 Prothena (PRTC) is a clinical-stage biopharmaceutical company that discovers and develops new drug candidates based on its proprietary platform and a founded entity model. It maintains a pipeline in the areas of pulmonary fibrosis, oncology, and neuropsychiatry, and is characterized by a structure in which its core assets are spun off into independent subsidiaries to drive value growth.
Over the past 1 year, roughly in the middle
13% below its 1-year high.
The price looks about right
Trading at - times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 1 quarters.
Tap to view numbers
Holding long would have lost money
Would have changed by -30.6% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 0.6%.
Tap to view numbers
It ranks #4 in the industry
Based on market cap of $424M.
PRTC $424M PER -
VRTX $131B PER 30.0
REGN $80B PER 19.3
ARGX $62B PER 37.5
FAQ
What kind of company is PRTC?
PRTC belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of PRTC?
The market cap of PRTC is approximately $424M, ranking 3,339 within its sector.
What is the 52-week high and low for PRTC?
PRTC has recorded a 52-week high of $19.92 and a low of $14.50.
